A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
Latest Information Update: 25 Nov 2021
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Bladder cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions
- 15 Nov 2021 Status changed from recruiting to discontinued.
- 09 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jul 2019).
- 08 Jun 2019 Planned End Date changed from 2 Aug 2020 to 2 Aug 2021.